JP2024156964A5 - - Google Patents

Download PDF

Info

Publication number
JP2024156964A5
JP2024156964A5 JP2024133744A JP2024133744A JP2024156964A5 JP 2024156964 A5 JP2024156964 A5 JP 2024156964A5 JP 2024133744 A JP2024133744 A JP 2024133744A JP 2024133744 A JP2024133744 A JP 2024133744A JP 2024156964 A5 JP2024156964 A5 JP 2024156964A5
Authority
JP
Japan
Prior art keywords
composition
kda
seq
protein
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024133744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024156964A (ja
JP7882546B2 (ja
Filing date
Publication date
Priority claimed from GBGB1807378.3A external-priority patent/GB201807378D0/en
Priority claimed from GBGB1807376.7A external-priority patent/GB201807376D0/en
Priority claimed from PCT/GB2019/051245 external-priority patent/WO2019211630A2/en
Application filed filed Critical
Publication of JP2024156964A publication Critical patent/JP2024156964A/ja
Publication of JP2024156964A5 publication Critical patent/JP2024156964A5/ja
Application granted granted Critical
Publication of JP7882546B2 publication Critical patent/JP7882546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024133744A 2018-05-04 2024-08-09 ワクチン組成物 Active JP7882546B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1807378.3A GB201807378D0 (en) 2018-05-04 2018-05-04 Vaccine composition
GBGB1807376.7A GB201807376D0 (en) 2018-05-04 2018-05-04 HMCV Vaccine Composition
GB1807378.3 2018-05-04
GB1807376.7 2018-05-04
PCT/GB2019/051245 WO2019211630A2 (en) 2018-05-04 2019-05-03 Vaccine composition
JP2021510553A JP7575096B2 (ja) 2018-05-04 2019-05-03 ワクチン組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021510553A Division JP7575096B2 (ja) 2018-05-04 2019-05-03 ワクチン組成物

Publications (3)

Publication Number Publication Date
JP2024156964A JP2024156964A (ja) 2024-11-06
JP2024156964A5 true JP2024156964A5 (cg-RX-API-DMAC10.html) 2025-01-21
JP7882546B2 JP7882546B2 (ja) 2026-06-30

Family

ID=66484095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510553A Active JP7575096B2 (ja) 2018-05-04 2019-05-03 ワクチン組成物
JP2024133744A Active JP7882546B2 (ja) 2018-05-04 2024-08-09 ワクチン組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021510553A Active JP7575096B2 (ja) 2018-05-04 2019-05-03 ワクチン組成物

Country Status (11)

Country Link
US (2) US12433944B2 (cg-RX-API-DMAC10.html)
EP (1) EP3787676A2 (cg-RX-API-DMAC10.html)
JP (2) JP7575096B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210013571A (cg-RX-API-DMAC10.html)
CN (2) CN112638411B (cg-RX-API-DMAC10.html)
AU (2) AU2019263706B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020022393A2 (cg-RX-API-DMAC10.html)
CA (1) CA3099381A1 (cg-RX-API-DMAC10.html)
IL (1) IL278418B2 (cg-RX-API-DMAC10.html)
SG (1) SG11202010821TA (cg-RX-API-DMAC10.html)
WO (1) WO2019211630A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433944B2 (en) * 2018-05-04 2025-10-07 SpyBiotech Limited Vaccine composition
GB201917265D0 (en) * 2019-11-27 2020-01-08 Univ Sheffield Bonded neurotoxins
AU2020402106A1 (en) 2019-12-11 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mumps and Measles virus immunogens and their use
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
WO2022129547A1 (en) * 2020-12-18 2022-06-23 University Of Copenhagen Nucleic acid vaccines
US20240240203A1 (en) * 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
US20250157651A1 (en) * 2022-01-19 2025-05-15 Trustees Of Dartmouth College Systems and methods for deterring viral transmission using neural networks
US12492266B2 (en) 2022-02-21 2025-12-09 Youcare Pharmaceutical Group Co., Ltd. Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof
CN115920026B (zh) * 2022-04-02 2023-11-14 中山大学 耐热性多聚体蛋白支架、耐热性多聚体蛋白支架在疫苗中的应用
CN115010812B (zh) * 2022-04-12 2024-06-21 河南省龙星生物科技有限公司 一种非洲猪瘟抗原介导细胞免疫的多聚体及应用
CN116041536A (zh) * 2022-09-15 2023-05-02 山西大学 一种多接头自组装蛋白纳米颗粒的制备方法与应用
CN117462666B (zh) * 2022-09-30 2024-07-30 烟台派诺生物技术有限公司 一种预防或治疗水痘-带状疱疹病毒相关疾病的免疫组合物产品及其制备方法
CN117264074A (zh) * 2023-01-12 2023-12-22 东沃同泰(凤城)生物工程有限公司 靶向DCs递送的耐热性纳米颗粒蛋白、纳米载体、免疫原性复合物和纳米颗粒疫苗及应用
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN117264081B (zh) * 2023-11-21 2025-03-21 华南理工大学 一种双肽受体激动剂及其制备方法与应用
CN118373888B (zh) * 2024-06-27 2024-08-30 普大生物科技(泰州)有限公司 一种水痘-带状疱疹病毒纳米颗粒蛋白及其制备方法和应用
WO2026028158A1 (en) * 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
WO2011009877A1 (de) 2009-07-24 2011-01-27 Basf Se Flammgeschützte polyamidformmassen
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
EP2614072A4 (en) 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
JP6232544B2 (ja) 2011-11-11 2017-11-22 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
AU2016207099C1 (en) * 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN106081304A (zh) 2016-07-27 2016-11-09 佛山市高明金荣华乐金属制品有限公司 一种新型可折叠箱体及其拆装方法
GB201705750D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd Peptide ligase and use therof
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
US12433944B2 (en) 2018-05-04 2025-10-07 SpyBiotech Limited Vaccine composition

Similar Documents

Publication Publication Date Title
JP7575096B2 (ja) ワクチン組成物
JP7189014B2 (ja) Rsvに対するワクチン
AU2007239354B2 (en) N protein fusion proteins of a virus in the Paramyxoviridae-protein of interest family
JP2023530434A (ja) コロナウイルスワクチン組成物、方法、及びその使用
CN112469661A (zh) 具有新结构组分的纳米粒疫苗
JP2013503159A5 (cg-RX-API-DMAC10.html)
CN101932594A (zh) 可用作疫苗的自装配肽纳米颗粒
JP2013501038A5 (cg-RX-API-DMAC10.html)
CN114929877A (zh) 突变型rsv f蛋白及其利用
JP2020536489A5 (cg-RX-API-DMAC10.html)
JP5545209B2 (ja) 免疫原性を有する物質
JP7602457B2 (ja) ペプチド核酸を基盤としたアジュバント
JP2021533772A (ja) フィロウイルス糖タンパク質の安定化された三量体
CN113430178A (zh) 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
Li et al. Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection
WO2002078732A1 (en) A noval vaccine formulation consisting of dna vaccine inactivated virus
HK40127919A (en) Vaccine composition
CN114409802B (zh) 禽流感病毒三聚体亚单位疫苗及其应用
CN120548366A (zh) 疫苗
HK40098178A (en) Human metapneumovirus vaccine
AU2001297689A1 (en) A noval vaccine formulation consisting of DNA vaccine inactivated virus
ZA200304631B (en) A novel vaccine formulation consisting of DNA vaccine inactivated virus.